This study provides a novel combination strategy for treating advanced cutaneous squamous cell carcinoma (cSCC), suggesting that adding EGFR-targeted therapy to anti-PD-(L)1 treatment may overcome primary or acquired resistance, offering direct reference value for optimizing cancer immunotherapy.
Literature Overview
The article titled 'A phase II (Alliance A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC)', published in the 'Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology', systematically investigates the efficacy and safety of combining the PD-L1 inhibitor avelumab with the EGFR monoclonal antibody cetuximab in advanced cutaneous squamous cell carcinoma (cSCC). Through a randomized controlled design, this study prospectively validates, for the first time, the synergistic potential of dual immune-targeted intervention, opening a new pathway for systemic treatment of this rare yet aggressive skin tumor.Background Knowledge
Advanced cutaneous squamous cell carcinoma (cSCC) is a highly invasive non-melanoma skin cancer with significant metastatic potential, particularly prevalent among immunocompromised individuals. Although anti-PD-1 antibodies such as cemiplimab and pembrolizumab have been approved for advanced cSCC and demonstrated objective response rates of approximately 30–46%, a substantial proportion of patients exhibit primary or secondary resistance, with limited median progression-free survival (PFS), highlighting an urgent need for more effective therapeutic strategies. A current bottleneck in PD-1/PD-L1 pathway inhibitor research is the difficulty in sustaining anti-tumor T-cell responses, especially within 'cold' tumor microenvironments. EGFR is frequently overexpressed in cSCC, and its signaling pathway not only promotes tumor proliferation but may also suppress local immune infiltration. Cetuximab, an IgG1-type EGFR monoclonal antibody, can not only block downstream signaling but also activate natural killer (NK) cells and dendritic cells (DCs) via antibody-dependent cellular cytotoxicity (ADCC), thereby promoting T-cell priming. Therefore, combining PD-L1 inhibition with EGFR-targeted therapy theoretically enables synergistic activation of both innate and adaptive immunity, reshaping the tumor immune microenvironment and overcoming the limitations of monotherapy with immune checkpoint inhibitors. This study is based on this mechanistic hypothesis, aiming to verify whether cetuximab can enhance the clinical activity of avelumab.
Research Methods and Experiments
The study employed a multicenter, randomized, phase II clinical trial design (Alliance A091802, NCT03944941), enrolling 57 patients with advanced cSCC who were naïve to anti-PD-1/PD-L1 therapy, and randomly assigned them in a 1:1 ratio to receive either avelumab plus cetuximab or avelumab monotherapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), clinical benefit rate, and safety. All patients underwent central testing for PD-L1 status using the tumor proportion score (TPS ≥1% defined as positive). In the combination arm, cetuximab was administered for one year, followed by maintenance avelumab monotherapy. The study design allowed patients in the avelumab monotherapy group to cross over to combination therapy upon disease progression, enabling evaluation of subsequent intervention efficacy. This design not only enhanced ethical acceptability but also provided insights for real-world clinical decision-making. Data analysis utilized the Cox proportional hazards model, with PFS and OS assessed using the Kaplan-Meier method, and subgroup analyses performed to explore potential biomarkers.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides key evidence for a paradigm shift in the treatment of advanced cSCC, confirming the clinical feasibility and superiority of dual targeting of PD-L1 and EGFR. From a research perspective, its significance lies not only in improved efficacy but also in validating that cetuximab-mediated activation of innate immunity (e.g., NK cells) can enhance adaptive immune responses to PD-(L)1 inhibitors, offering an actionable mechanistic pathway to overcome immunotherapy resistance. For drug development, these results support conducting larger phase III trials comparing cetuximab combined with standard anti-PD-1 antibodies (e.g., pembrolizumab) versus monotherapy as first-line treatment. For clinical monitoring, future work should deeply analyze dynamic changes in the tumor microenvironment and explore associations between biomarkers such as T-cell clonality and IFN-γ signaling and treatment outcomes. For disease modeling, genetically engineered mouse models of cSCC can be developed to simulate dual features of EGFR overexpression and PD-L1 upregulation, enabling mechanistic validation and novel drug screening.
Conclusion
This study establishes avelumab plus cetuximab as a treatment regimen with significant PFS advantage in advanced cutaneous squamous cell carcinoma, offering renewed hope for the systemic management of this rare but clinically challenging malignancy. Its core value lies in prospectively demonstrating through a randomized trial that EGFR targeting not only directly inhibits tumor growth but also reshapes the immune microenvironment via mechanisms such as ADCC, thereby enhancing the efficacy of PD-(L)1 inhibitors. This 'immune-targeted' combination strategy holds direct translational significance for cSCC patients and provides a reference framework for other EGFR-driven squamous cell carcinomas, such as head and neck squamous cell carcinoma. Future research should focus on optimizing patient selection, exploring safer and more effective combination regimens, and deeply elucidating the cellular and molecular mechanisms underlying synergistic anti-tumor immunity. From bench to bedside, this study provides a solid foundation for building more precise and durable anti-tumor immune responses, potentially reshaping the care paradigm for cSCC and advancing personalized immunotherapy.
